YF-VAX 1 dose vials
Ended Awarded Last action
- Contract number
- SPE2DR26FFLP4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,259
Award facts
- Contract value 100% obligated
- $1,259.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $1,259.08 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Yellow Fever vaccine (YF-VAX) in single-dose vial format. The delivery order, issued on January 23, 2026, with an ultimate completion date of February 13, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This award represents a discrete purchase order executed under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative.
DMS Pharmaceutical Group holds a single-award IDC valued at $499.999 billion through December 31, 2036, positioning the company as a critical pharmaceutical supplier for Department of Defense military healthcare facilities worldwide. The PPV-G GEN V represents part of DLA's comprehensive $30.3 billion pharmaceutical supply strategy designed to deliver firm fixed-price orders for branded and generic prescription drugs, biologics, vaccines, and medical consumables to support recurring DoD medical supply requirements globally. DMS Pharmaceutical Group's established performance across numerous delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system, with this YF-VAX delivery order exemplifying the routine vaccine procurement executed through the prime vendor framework.
Quick answers
Who was awarded contract SPE2DR26FFLP4?
SPE2DR26FFLP4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 23, 2026.
How much is contract SPE2DR26FFLP4 worth?
The government has obligated $1,259 on SPE2DR26FFLP4.
Is contract SPE2DR26FFLP4 an order under another contract?
Yes. SPE2DR26FFLP4 is a delivery order under SPE2DR25D9227, an indefinite delivery contract.
Was contract SPE2DR26FFLP4 competed?
The extent of competition for SPE2DR26FFLP4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award